IPSC
IPSC clinical trials: Century Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Century Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IPSC on the catalyst calendar · IPSC registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Aug 2028Sponsor estimate | NCT06255028A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesCentury Therapeutics, Inc. · Systemic Lupus Erythematosus | IPSCLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Jul 1, 2025Actual | NCT05336409A Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesCentury Therapeutics, Inc. · R/R CD19-Positive B-Cell Malignancies | IPSCLead | Phase 1 | Terminated | Locked | Locked | Locked |
| Mar 2040Sponsor estimate | NCT05768269A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy ProductCentury Therapeutics, Inc. · Hematological Malignancy | IPSCLead | No phase registered | Recruiting | Locked | Locked | Locked |
- Primary completion Aug 2028Sponsor estimatePhase 1NCT06255028A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune DiseasesCentury Therapeutics, Inc. · Systemic Lupus ErythematosusActive, not recruitingIPSCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2025ActualPhase 1NCT05336409A Study of CNTY-101 in Participants With CD19-Positive B-Cell MalignanciesCentury Therapeutics, Inc. · R/R CD19-Positive B-Cell MalignanciesTerminatedIPSCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2040Sponsor estimateNo phase registeredNCT05768269A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy ProductCentury Therapeutics, Inc. · Hematological MalignancyRecruitingIPSCLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner